Lord, Abbett & Co
NEO icon

Lord, Abbett & Co’s NeoGenomics NEO Stock Holding History

Lord, Abbett & Co’s Portfolio NEO Stock Details NEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-196,400
Closed -$819K – 939
2014
Q4 		$819K Buy
+196,400
New +$902K ﹤0.01% 900

Other funds holding NEO

CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
CAM
Cortina Asset Management Milwaukee, Wisconsin $1.62B AUM 15.44% 1-Year Est. Return
TAM
THB Asset Management Norwalk, Connecticut $440M AUM 59.59% 1-Year Est. Return
KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return

Lord, Abbett & Co's NEO Position: Q1 2015 in Review

Lord, Abbett & Co sold out of NeoGenomics (NEO) in Q1 2015, closing a stake of 196,400 shares — an estimated $819K sold.

Lord, Abbett & Co first reported a position in NEO in Q4 2014 and held it in 1 quarter. The position peaked at $819K in Q4 2014. 84 funds tracked by Wall St. Rank hold NEO as of Q1 2015.

  • Lord, Abbett & Co reported no remaining NeoGenomics position as of Q1 2015 after selling out during the quarter.
  • Lord, Abbett & Co sold 196,400 NeoGenomics shares in Q1 2015, an estimated $819K.
  • Lord, Abbett & Co first reported a position in NeoGenomics in Q4 2014 and held it in 1 quarter.
  • Lord, Abbett & Co's NeoGenomics position peaked at $819K in Q4 2014.
  • 84 funds tracked by Wall St. Rank held NeoGenomics as of Q1 2015.

Based on Lord, Abbett & Co's 13F filing for Q1 2015, filed 15 May 2015.